Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. It follows the recently announced positive recommendation by the European Medicines Agency (Committee for Medicinal Products for Human Use), and last year’s landmark approval by the U.S. Food and Drug Administration.
This milestone moment in NF is the result of patients, families, researchers, clinicians, doctors, nurses, pharma, biotech, government, donors and friends and so many more working TOGETHER to #ENDNF. And we promise: we are not done. We will not stop until there are treatments for ALL types of NF!
